Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H N Glassman

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The American Journal of Medicine|May 23, 1986
Efficacy of terazosin as an antihypertensive agentR R Luther, H N Glassman, D C Jordan, et al.
Arzneimittel-Forschung|January 1, 1989
Renin inhibitors: specific modulators of the renin-angiotensin systemR R Luther, H H Stein, H N Glassman, et al.
The American Journal of Medicine|May 23, 1986
Overall safety of terazosin as an antihypertensive agentW D Sperzel, H N Glassman, D C Jordan, et al.
The Journal of International Medical Research|January 1, 1986
Long-term treatment of angina pectoris with carteolol: a new beta-adrenergic receptor blocking agentR R Luther, H N Glassman, D C Jordan, et al.
American Heart Journal|April 1, 1989
The effects of terazosin and methyclothiazide on blood pressure and serum lipidsR R Luther, H N Glassman, C B Estep, et al.
Circulation|June 1, 1990
Assessment of renin dependency of hypertension with a dipeptide renin inhibitorM A Weber, J M Neutel, I Essinger, et al.
Journal of Human Hypertension|April 1, 1990
Effects of terazosin on serum lipid levels in hypertensive blacksR R Luther, M J Klepper, C J Maurath, et al.
Circulation|January 15, 1995
Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjectsJ Ménard, R S Boger, D M Moyse, et al.
Journal of Human Hypertension|April 1, 1990
Efficacy of terazosin in the treatment of essential hypertension in blacksR R Luther, M J Klepper, C J Maurath, et al.
Journal of Cardiovascular Pharmacology|January 1, 1990
Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitorH N Glassman, H D Kleinert, R S Boger, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The American Journal of Medicine|May 23, 1986
Efficacy of terazosin as an antihypertensive agentR R Luther, H N Glassman, D C Jordan, et al.
Arzneimittel-Forschung|January 1, 1989
Renin inhibitors: specific modulators of the renin-angiotensin systemR R Luther, H H Stein, H N Glassman, et al.
The American Journal of Medicine|May 23, 1986
Overall safety of terazosin as an antihypertensive agentW D Sperzel, H N Glassman, D C Jordan, et al.
The Journal of International Medical Research|January 1, 1986
Long-term treatment of angina pectoris with carteolol: a new beta-adrenergic receptor blocking agentR R Luther, H N Glassman, D C Jordan, et al.
American Heart Journal|April 1, 1989
The effects of terazosin and methyclothiazide on blood pressure and serum lipidsR R Luther, H N Glassman, C B Estep, et al.
Circulation|June 1, 1990
Assessment of renin dependency of hypertension with a dipeptide renin inhibitorM A Weber, J M Neutel, I Essinger, et al.
Journal of Human Hypertension|April 1, 1990
Effects of terazosin on serum lipid levels in hypertensive blacksR R Luther, M J Klepper, C J Maurath, et al.
Circulation|January 15, 1995
Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjectsJ Ménard, R S Boger, D M Moyse, et al.
Journal of Human Hypertension|April 1, 1990
Efficacy of terazosin in the treatment of essential hypertension in blacksR R Luther, M J Klepper, C J Maurath, et al.
Journal of Cardiovascular Pharmacology|January 1, 1990
Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitorH N Glassman, H D Kleinert, R S Boger, et al.
Pageof 3